Corbus Pharmaceuticals Holdings, Inc. · NASDAQ:CRBP

Corbus Pharmaceuticals — Investor Presentation (November 2023)

58 slides from Corbus Pharmaceuticals's investor presentation, Nov 14, 2023

  1. Slide 1: Connecting Innovation to Purpose: Corporate Presentation November 2023

    Connecting Innovation to Purpose Corporate Presentation November 2023 NASDAQ: CRBP • CorbusPharma.com • @CorbusPharma Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Co

  3. Slide 3: A diversified pipeline with differentiated clinical risk profiles

    Next Generation Nectin-4 targeting ADC CRB-701 Next generation Nectin-4 targeting ADC Nectin-4 positive solid tumors CSPC (China) Dose Escalation Started Q1 2023 Ends Q4 2023 Dose Confirmation / Expansion Start Q1 2024 Corbus (US + Europe) Dose Escalation Planned start Q1 2024 End Q2 2024 Dose Confi

  4. Slide 4: CRB-701 Next Gen Nectin-4 Targeting ADC

    CRB-701 Next Gen Nectin-4 Targeting ADC

  5. Slide 5: CRB-701 summary

    CRB-701 summary Designed to offer improved therapeutic index over Padcev® Ph1 dose escalation ongoing in Nectin-4 tumors with first data release Q1 2024 Emerging clinical data supports differentiated ADC profile

  6. Slide 6: Padcev projected to reach up to ~$5B in global sales

    Padcev® projected to reach up to ~$5B in global sales by 2028 $5B ® Latest Padcev® Q3 revenues 1 22nd October 2023 2 Sources: 1. SGEN Q3 earnings report, 2. SGEN press release, October 2023, 3. Evaluate Pharma

  7. Slide 7: Does tolerability for Padcev impact clinical adoption?

    Does tolerability for Padcev® impact clinical adoption? ® Duration of Response ~5 months 47% Rate of Serious Adverse Events (SAEs) 61% Dose interruptions 34% Dose reductions 17% Dose Discontinuations Revised: 4/2023 PADCEV® Prescribing Information Source(s): PADCEV® Prescribing Information as of Apr

  8. Slide 8: Padcev is associated with skin toxicities and peripheral neuropathy

    Padcev® is associated with skin toxicities and peripheral neuropathy PADCEV® monotherapy1 PADCEV® + Keytruda2 All Grades ≥ Gr 3 All Grades ≥ Gr 3 Skin Reactions 56% 12% 67% 16% Sensory Peripheral Neuropathy 53% 5% 59% 4.3% Motor Peripheral Neuropathy NR NR 10% 2.7% PADCEV® Adverse Events (% of patie

  9. Slide 9: Is the 2nd generation Seagen linker the cause?

    Is the 2nd generation Seagen linker the cause? Skin Rash Peripheral Neuropathy Similar dose limiting toxicities seen across divergent ADCs that share same constellation of ‘linker + payload’ Val-Cit linker + vedotin (MMAE) payload All grades ADC drug TAA Average DAR Padcev® Enfortumab vedotin Nectin

  10. Slide 10: Real-world use, dose intensity, and adherence to Padcev

    Monotherapy Padcev® Source(s): 1. PADCEV® Prescribing Information as of Dec 2019, 3. Redacted from Tsingas et al., ASCO 2023 6 months of therapy = ~ 54 hours of total clinic time / patient Real-world use, dose intensity, and adherence to Padcev® Padcev® requires frequent dosing and is used different

  11. Slide 11: Emerging clinical-stage competition is not solving for existing challenges

    Emerging clinical-stage competition is not solving for existing challenges Limitation Padcev® BT8009 9MW-2821 Upper dose limit 1.25 mg/kg 1 5 mg/m2 4 1.25 mg/kg 3 Schedule D1, D8, D15 /28 days Q1W D1, D8, D15 /28 days ≥ Grade 3 AE rate 51% (n=155) 2 65% (n=20) 6 35% (n=85) 3 Peripheral Neuropathy 38

  12. Slide 12: Designing a Nectin-4 ADC that addresses Padcev unmet needs

    Designing a Nectin-4 ADC that addresses Padcev® unmet needs Toxicity: Use 3rd gen linker  Reduce free circulating MMAE Compliance: Extend ADC half-life  Reduce dosing frequency Efficacy: Lower DAR + longer half-life  Dose higher than Padcev®

  13. Slide 13: CRB-701: Next generation site-specific Nectin-4 targeting ADC

    CRB-701: Next generation site-specific Nectin-4 targeting ADC Source(s): Modified image from Corbus data on file; Corbus data on file MMAE = Monomethyl auristatin E ADCC = antibody-dependent cellular cytotoxicity CDC = complement dependent cytotoxicity DAR = Drug Antibody Ratio

  14. Slide 14: CRB-701: Once in 21-days schedule offers significant advantages

    CRB-701: Once in 21-days schedule offers significant advantages Padcev® CRB-701 Patient / physician convenience Combination flexibility Clinical cycle comparison Source(s): Corbus data on file; PADCEV® Prescribing Information as of Dec 2019

  15. Slide 15: CRB-701: Clinical PK demonstrates lower free-MMAE than Padcev

    CRB-701: Clinical PK demonstrates lower free-MMAE than Padcev® 15 Corbus Pharmaceuticals - Confidential Comparisons of payload in plasma across Padcev® and CRB-701 CRB-701 PADCEV® Dose level 1 4% Dose level 2 10% Dose level 4 ? Dose level 5 ? Dose level 6 ? Dose level 7 ? 1.2 mg/kg 30% Padcev® 1.25

  16. Slide 16: CRB-701: Already dosing significantly above the Padcev dose

    CRB-701: Already dosing significantly above the Padcev® dose 16 Corbus Pharmaceuticals - Confidential Dose level 1 No DLT Dose level 2 No DLT 1.2 mg/kg No DLT Dose level 4 No DLT Dose level 5 No DLT Dose level 6 Dose level 7 0.5 mg/kg 0.75 mg/kg 1 mg/kg 1.25 mg/kg Enrolling RP2D CRB-701 PADCEV® Data

  17. Slide 17: CRB-701: A differentiated clinical development approach

    CRB-701: A differentiated clinical development approach to competitors mUC New reality of Padcev® + Keytruda® 1L therapy Under-served niche mUC populations remain and are attractive targets Other Nectin-4 solid tumors Emerging clinical data from current dose escalation is informative Focus on unexpl

  18. Slide 18: Validation of Nectin-4 as a Tumor Associated Antigen beyond mUC

    Validation of Nectin-4 as a Tumor Associated Antigen beyond mUC Parameter Patients (N=46) Confirmed ORR 11 (23.9%) CR 1 (2.2%) PR 10 (21.7%) SD 15 (32.6%) mPFS 3.94 months Source: Corbus data on file, Swiecicki et al., Abstract 6017., ASCO 2023 Elevated Nectin-4 expression: urothelial, breast, ovari

  19. Slide 19: Clinical Status: Non-clinical / Clinical Development plan

    Clinical Status: Non-clinical / Clinical Development plan 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2 2025 Q3 CRB-701 Development Timeline China US/EU Non-clinical validation of Nectin-4 US RP2D Escalation (6 step) Nonclinical US CDx vendor selection Expansion (5)

  20. Slide 20: CRB-701: Summary

    CRB-701: Summary Emerging clinical safety profile supports higher dosing Replaced need for frequent dosing 3rd generation linker improves stability and reduces MMAE in circulation

  21. Slide 21: CRB-913: oral CB1 inverse agonist for superior incretin therapy in obesity

    CRB-913: oral cannabinoid type-1 inverse agonist for superior incretin therapy in obesity NASDAQ: CRBP • CorbusPharma.com • @CorbusPharma

  22. Slide 22: Incretin analogs have transformed the field of obesity

    Incretin analogs have transformed the field of obesity and its commercial value Muscle loss Tolerability Accessibility  Long-term compliance is ~ 27% Source(s): RBC report Oct 2023 But…

  23. Slide 23: The obesity landscape is evolving to address these issues

    The obesity landscape is evolving to address these issues Muscle loss: Degree of weight loss  Quality of weight loss Tolerability: Single MOA  Multiple orthogonal MOAs Accessibility: Injectables  Oral small molecules Source(s): RBC report Oct 2023

  24. Slide 24: CB1 inverse agonism: The return of a clinically-validated obesity drug class

    CB1 inverse agonism: The return of a clinically-validated obesity drug class 24

  25. Slide 25: The CB1 MOA is clinically validated in obesity: data from 1st gen drugs

    -9.0% -4.4% -2.4% % weight loss RIO-Lipids Phase 3 study Placebo (n=342); 5 mg rimonabant (n=345); 20 mg rimonabant (n=346) Completed Phase 3 studies (2 and 4 mg) (2 yr) Placebo (n=417); 2 mg taranabant (n=414); 4 mg taranabant (n=415) % weight loss -8.1% -6.6% -2.6% Rimonabant1 Taranabant2 Source(s

  26. Slide 26: Next gen CB1 inverse agonists are peripherally restricted

    Next gen CB1 inverse agonists are peripherally restricted 1st gen (2000-2007) Next gen (2020 onwards) Designed to target the brain with high BBB penetration  FDA rejection due to safety concerns (2007) Designed to be peripherally restricted with minimal BBB penetration  avoid safety issues Rimonab

  27. Slide 27: Novo Nordisk acquisition of Inversago marks return of CB1 in obesity

    Novo Nordisk acquisition of Inversago marks return of CB1 as an MOA in obesity Single-dose INV-202 (25mg QD) N = 37 Adults with metabolic syndrome Weight loss: -3.50 kg (INV-202) vs +0.55Kg (placebo) In line with 20mg QD rimonabant efficacy Aug. 10, 2023 Source(s): Inversago corporate presentation

  28. Slide 28: CRB-913: oral CB1 inverse agonist for combination therapy with incretins

    CRB-913: oral CB1 inverse agonist for combination therapy with incretins 28 Nov. 2023

  29. Slide 29: CRB-913: designed to be a best-in-class next gen CB1 inverse agonist

    CRB-913: designed to be a best-in-class next gen CB1 inverse agonist Design goals: Best-in-class peripheral restriction Protect lean mass (muscle) Retain 1st gen efficacy Enhance efficacy of incretin analogs

  30. Slide 30: Oral CRB-913 is the outcome of a multi-year medicinal chemistry campaign

    Ibipinabant (2004-2008) JD-5037 (2012-2018) / CRB-4001 (2018-2021) Completed Phase IIb (Solvay/BMS) Small, lipid soluble molecule High BBB penetration Oral CRB-4001 (JD5037) licensed from Jenrin in 2018 Extensive pre-IND studies carried out PK didn’t support TPP Oral CRB-913 New IP published –patent

  31. Slide 31: CRB-913: marked peripheral restriction vs. rimonabant

    Source(s): Morningstar et al 2023 CRB-913: marked peripheral restriction vs. rimonabant in both lean and obese mice concentration (ng/g) concentration (ng/g) 10 mg/Kg Co-administration with incretin analog does not affect brain penetration for CRB-913

  32. Slide 32: CRB-913: higher degree of peripheral restriction than INV-202

    Source(s): Morningstar et al 2023 and Liu et al 2021 CRB-913: higher degree of peripheral restriction than INV-202 Brain concentration (ng/g) single acute dose CRB-913 (lean mice) INV-202 (lean mice) fold difference 10 mg/Kg 26 319 1:12

  33. Slide 33: CRB-913: similar weight loss vs rimonabant at same daily doses

    Source(s): Morningstar et al 2023 CRB-913: similar weight loss vs rimonabant at same daily doses in DIO mice

  34. Slide 34: CRB-913: similar weight loss despite markedly lower brain concentrations

    21-fold DIO mouse model (day 28) DIO mouse model with C57BL6/N mice (n=10) fed a continuous high fat diet for 22 weeks prior and during 28 days of treatment Brain collected 1 h post final dose (Cmax) Source(s): Company data on file. CRB-913: similar weight loss despite markedly lower brain concentra

  35. Slide 35: CRB-913 reduces body fat content but not lean mass

    DIO mouse model with C57BL6/J mice (n=10) fed a continuous high fat diet for 22 weeks prior Body fat by MRI determined on Day 20 Source(s): Morningstar et al 2023 CRB-913 demonstrates significant reduction in body fat content but not lean mass weight (g) Body Fat Lean Mass Body composition was measu

  36. Slide 36: CRB-913: enhanced combo effect with semaglutide or tirzepatide

    CRB-913: enhanced combo effect with semaglutide or tirzepatide Source(s): Company data on file. DIO mouse model with C57BL6/J mice (n=10) fed a continuous high fat diet for 22 weeks prior and during 18 days of treatment (Similar effect also seen when CRB-913 was combined with liraglutide) Body weigh

  37. Slide 37: CRB-913 reduces food consumption alone or in combination

    CRB-913 reduces food consumption alone or in combination with semaglutide or tirzepatide Source(s): Company data on file. Food Consumption CRB-913, semaglutide and tirzepatide each results in food intake reductions Significant further reductions in food consumption when CRB-913 is combined with sema

  38. Slide 38: CRB-913 reverses leptinemia alone and in combination

    CRB-913 reverses leptinemia alone and in combination with semaglutide or tirzepatide Source(s): 1 Leptin and the maintenance of elevated body weight, Pan and Myers, Nature Reviews, Jan 2018. Company data on file. The Role of Leptin The hormone leptin regulates food intake Normally, leptin signals sa

  39. Slide 39: CRB-913 reduces liver fat alone and in combination

    CRB-913 reduces liver fat alone and in combination with semaglutide or tirzepatide *liver oil red stain Source(s): Company data on file. 39 vehicle CRB-913 (2.5 mg/kg) semaglutide (10 nmol/kg) CRB-913 (2.5 mg/kg) + semaglutide (10 nmol/kg) tirzepatide (5 nmol/kg) CRB-913 (2.5 mg/kg) + tirzepatide (5

  40. Slide 40: CRB-913: Clinical development pathway and potential clinical usage

    CRB-913: Clinical development pathway and potential clinical usage IND H2 2024 SAD  MAD H1 2025 Monotherapy 28 days (3 doses) H2 ‘25 – H1 ‘26 Co-admin with incretin analog H2 ‘26 – H1 ‘27 Potential clinical applications: Incretin analog therapy insensitive/intolerant/high-risk patients Combination

  41. Slide 41: CRB-913: designed to be a best-in-class next gen CB1 inverse agonist

    CRB-913: designed to be a best-in-class next gen CB1 inverse agonist Best-in-class peripheral restriction Protect lean mass (muscle) Retain 1st gen efficacy Enhance efficacy of incretin analogs

  42. Slide 42: Leadership, Financials, Upcoming catalysts

    Leadership Financials Upcoming catalysts

  43. Slide 43: Management Team

    Management Team Yuval Cohen, PhD Chief Executive Officer, Director Corbus co-founder and Chief Executive Officer since 2014. Previously the President and co-founder of Celsus Therapeutics from 2005. Sean Moran, CPA, MBA Chief Financial Officer Corbus co-founder and Chief Financial Officer since 2014.

  44. Slide 44: Board of Directors

    Board of Directors Amb. Alan Holmer Ret. Chairman of the Board More than two decades of public service in Washington, D.C. including Special Envoy to China; Former CEO of PhRMA. Avery W. (Chip) Catlin Director More than 25 years of senior financial leadership experience in life science companies; For

  45. Slide 45: 2023 - 2024 Catalysts

    AACR 2023 - 2024 Catalysts 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 CRB - 601 ⍺vβ8 mAb CRB - 701 Nectin-4 targeting ADC IND FPI AACR-NCI-EORTC TGFβ Summit NYAS Conference presentation Clinical milestone SITC PK = PharmacoKinetics CDx = Companion Diagnostic RP2D = Recommended P

  46. Slide 46: Investment Summary

    Investment Summary Advancing anti-⍺vβ8 integrin program to IND submission in Q4 2023 CRBP Ticker $29 Million Focus on developing precision oncology + differentiated assets Clinically developing a next generation Nectin-4 targeting ADC Cash, cash equivalents and investments as of September 30, 2023 4

  47. Slide 47: Corbus Pharmaceuticals

    CORBUS %” PHARMACEUTICALS

  48. Slide 48: CRB-601 Potential best-in-class avb8 mAb

    CRB-601 Potential “best-in-class” ⍺vβ8 mAb

  49. Slide 49: CRB-601 has the potential to enhance checkpoint inhibition

    CRB-601 has the potential to enhance checkpoint inhibition Focus on adopting a precision-targeted approach Novel mechanism to target TGFb in the tumor microenvironment Large opportunity potential if POC is validated

  50. Slide 50: Targeting the integrin avb8 represents a novel approach to regulating TGFb

    Targeting the integrin ⍺vβ8 represents a novel approach to regulating TGFβ Source(s): Huang et al., 2021. Recent progress in TGFβ inhibitors for cancer therapy.

  51. Slide 51: CRB-601 is targeting latent-TGFb by blocking the integrin avb8

    CRB-601 is targeting latent -TGFβ by blocking the integrin avb8 The integrin avb8 is expressed in the tumor microenvironment (TME) Latent-TGFb is also expressed in the TME CRB-601 is a blocking antibody preventing the interaction of these two proteins

  52. Slide 52: mAbs targeting TGFb activation are advancing clinically

    mAbs targeting TGFβ activation are advancing clinically Source(s): Company websites. Clinicaltrials.gov. Internal analysis. CRB-601 PF-06940434 SRK-181 ABBV-151 RG6440 MOA ⍺vβ8 ⍺vβ8 L-TGFβ GARP (TGFβ1) L-TGFβ Clinical Stage IND in Q4 2023 Phase 1/2 updated July 2023 Phase 1 Phase 2 updated July 2023

  53. Slide 53: CRB-601 enhances anti-PD-1 therapy in murine tumor models

    CRB-601 enhances anti-PD-1 therapy in checkpoint inhibition sensitive and resistant murine tumor models CRB-601: 10 mg/kg BIW Anti-PD-1: 10 mg/kg BIW 10 animals / group Animals randomized at 50-80 mm3 Comparisons across arms *p<0.05, ***p<0.001, ****p<0.0001 % TGI MC38 EMT6 4T1 Anti-PD-1 54 -8 6 CRB

  54. Slide 54: Blockade of avb8 with anti-PD-1 increased TIL populations in EMT6 tumors

    Blockade of ⍺vβ8 in combination with anti-PD-1 increased TIL populations in immune excluded EMT6 tumors **** *** **** **** **** *** **** **** Ki67+CD4 T Cells Ki67+CD8 T Cells CD4 T Cells CD8 T Cells Tumor Size * *** * **** ** *** ** *** ** **** * **** * Treatment Days -14 0 3 6 10 Anti-PD-1, 10 mg/

  55. Slide 55: CRB-601 reshapes the landscape of effector T and NK cells in MC38 tumors

    CRB-601 Reshapes the landscape of effector T and NK cells in MC38 tumors Source(s): Corbus data on file

  56. Slide 56: Applying a proprietary algorithm to define the clinical focus for CRB-601

    Applying a proprietary algorithm to define the clinical focus for CRB-601 A multi-parametric, immune-focused algorithm has refined indications for CRB-601 The combination of immune features and gene expression profiles have identified 9 indications for clinical priority High Low Quartiles Source(s):

  57. Slide 57: Patient selection strategies will enhance the probability of success

    Patient selection strategies will enhance the probability of success Source(s): Corbus proprietary analysis: Log2 fold change of Nectin-4 expression as a ratio to normal tissue Controls Ovarian Melanoma Breast Colon Prioritization of indications with differential gene expression vs. normal tissues w

  58. Slide 58: CRB-601 Next Steps

    CRB-601 Next Steps IND filing scheduled for H2-2023 FPI expected H1-2024 Non-clinical validation of a potential patient selection biomarker in 2023 Dose escalation and confirmation will be the focus through 2024

Corbus Pharmaceuticals Holdings — Investor Presentation (November 2023) on 6ix